Fig. 7: A hypothetical model deciphering the mechanisms of EZN-sensitive and ENZ-resistant CRPC.
From: A noncanonical AR addiction drives enzalutamide resistance in prostate cancer

AR androgen receptor, ARE androgen response element, ac acetylation, CRPC castration-resistant prostate cancer, NEPC neuroendocrine prostate cancer, DNPC double-negative (AR-null/neuroendocrine-null) prostate cancers, GR glucocorticoid receptor, CXXC5 CXXC Finger Protein 5, TET2 Tet Methylcytosine Dioxygenase 2, BRD4 Bromodomain-containing protein 4, p300 Histone acetyltransferase p300.